You can buy or sell DCPH and other stocks, options, ETFs, and crypto commission-free!
Deciphera Pharmaceuticals, Inc. operates as a biotechnology company which develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. The company designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. Read More It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.
52 Week High
52 Week Low
Yahoo FinanceMay 9
Deciphera Pharmaceuticals, Inc. Announces First Quarter 2019 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)-- - Top-line Data from INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Fourth-line and Fourth-line Plus GIST Patients Expected in Mid-2019 - - Recommended Phase 2 Dose Selected for Part 2 of Phase 1b/2 Study of Rebastinib plus Paclitaxel; Enrollment in Part 2 with Expansion Cohorts Expected to Commence Second Quarter 2019 - - Ended First Quarter 2019 with Cash, Cash Equivalents and Marketable Securities of $262 Million - Deciphera Pharmaceuticals, Inc. (DCPH), a ...
Yahoo FinanceMay 4
Here’s What Hedge Funds Think About Deciphera Pharmaceuticals, Inc. (DCPH)
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the future holds and how market participants will react to the bountiful news that floods in each day. Hedge funds underperform because they are hedged. The Standard and Poor’s 500 Index returned appr...
Expected Aug 7, After Hours